Home › Acute biphenotypische leukemie › Oklahoma
Acute biphenotypische leukemie klinische studies in Oklahoma
5 studies voor Acute biphenotypische leukemie zoeken deelnemers op locaties in Oklahoma.
Steden in Oklahoma
Officiële studietekst (Engels)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruterenFase 2
365 Days · Alle geslachten · Bijgewerkt 25 sep. 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
RekruterenFase 3
365 Days – 25 Years · Alle geslachten · Bijgewerkt 25 aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruterenFase 1/2
Tot leeftijd 22 · Alle geslachten · Bijgewerkt 25 aug. 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Saint Francis Children's Hospital, Tulsa
RekruterenFase 2
Leeftijden 1 tot 18 · Alle geslachten · Bijgewerkt 10 aug. 2026 · NCT06390319Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Saint Francis Children's Hospital, Tulsa
RekruterenFase 4
Leeftijden 1 tot 18 · Alle geslachten · Bijgewerkt 14 jul. 2026 · NCT06289673Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.